Medicine › Oncology

Cancer Diagnosis and Treatment

Works Count: 79766

Wikipedia

Description

This cluster of papers focuses on the diagnosis, treatment, and molecular characterization of Cancer of Unknown Primary (CUP) site. It includes research on metastatic patterns, molecular profiling to identify tissue of origin, immunohistochemical markers, diagnostic algorithms, and clinical management strategies.

Keywords

Cancer of Unknown Primary; Metastasis; Tissue of Origin; Molecular Profiling; Immunohistochemistry; Diagnostic Algorithm; Soft Tissue Metastases; Gene Expression Profiling; Unknown Primary Tumours; Clinical Management

Pathology of Tumours of the Oral Tissues

1977-06-01

R. B. Lucas

This book is not intended as a text- book, but it is a well-produced mono- graph which is a reflection of the work of an expert and a worthy broadside … This book is not intended as a text- book, but it is a well-produced mono- graph which is a reflection of the work of an expert and a worthy broadside into the ranks of those who still support the single contrast barium enema.

View PDF Chat

Cutaneous Metastasis: A Meta-Analysis of Data

2003-02-01

RICHARD A. KRATHEN , Ida Orengo , Ted Rosén

Previous studies of the incidence and the most common causes of cutaneous metastasis have not led to a consensus. We compiled data from many retrospective studies and from patient data … Previous studies of the incidence and the most common causes of cutaneous metastasis have not led to a consensus. We compiled data from many retrospective studies and from patient data registries and autopsies to increase the total number of cases available for a larger analysis of this subject. This study was conducted to gain a better understanding of the true incidence of cutaneous metastasis, the tumors most commonly involved in this presentation, and the locations of such lesions.A meta-analysis of cutaneous metastases from patient tumor registries and autopsic studies was performed.The overall incidence of cutaneous metastasis is 5.3%. The most common tumor to metastasize to the skin is breast cancer. The chest is the most common site of cutaneous metastasis. Every practitioner should be highly suspicious of acute-onset, persistent, firm papulonodules, especially when they develop on the chest.This meta-analysis greatly increases the total number of cases available for the analysis of cutaneous metastases and provides a better overall view of this topic than was previously possible.

Diagnostic histopathology of tumors

2013-12-15

edited by Christopher D.M. Fletcher.

Clinical Radiation Oncology

2016-01-01

Leonard L. Gunderson , Joel E. Tepper

Diagnostic surgical pathology

1994-01-01

Stephen S. Sternberg , Donald A. Antonioli

Vol 1: skin, soft tissue, bone, and joints - nonneoplastic diseases of the skin, Alvin R. Solomon, neoplasms of skin, Daniel J. Santa Cruz and Mark A. Hurt, melanocytic lesions, … Vol 1: skin, soft tissue, bone, and joints - nonneoplastic diseases of the skin, Alvin R. Solomon, neoplasms of skin, Daniel J. Santa Cruz and Mark A. Hurt, melanocytic lesions, Michael J. Imber and Martin C. Mihm, Jr, muscle biopsy in neuromuscular disorders, Reid R. Heffner, Jr, disorders of soft tissue, John J. Brooks, joint diseases, Peter G. Bullough, nonneoplastic disease of bones, Peter G. Bullough, bone tumours, K. Krishnan Unni breast - the breast, Rosemary R. Millis, et al central nervous system - the brain, spinal cord, and meninges, Paul E. McKeever and Mila Blaivas endocrine system - the pituitary and sellar region, Bernd W. Scheithauer, the thyroid and parathyroid, Virginia A. LiVolsi, the neuroendocrine and paracrine systems, Ricardo V. Lloyd, the adrenal glands, Ronald A. DeLellis, paragangliomas, Ernest E. Lack hematopoietic and lymphatic systems - disorders of bone marrow, Robert W. McKenna, lymph nodes, Robert D. Collins, et al, the spleen, Jerome S. Burke head and neck - the jaws and oral cavity, Kenneth D. McClatchey and Richard J. Zarbo, salivary glands, Andrew G. Huvos, the nose, paranasal sinuses, and nasopharynx, Stacey E. Mills and Robert E. Fechner, the larynx, John A. Kirchner and Darryl Carter, the ear, Leslie Michaels, the eye and ocular adnexa, Mark W. Scroggs and Gordon K. Klintworth intrathoracic organs and blood vessels - nonneoplastic pulmonary disease, Arthur S. Patchefsky, pulmonary neoplasms, Yukio Shimosato, the pleura, Hector Battifora, the mediastinum, Mark R. Wick, the heart, H. Thomas Aretz, blood vessels, Patrick J. Gallagher. Vol 2: alimentary canal and associated organs - esophagus, Randall G. Lee, stomach, David A. Owen, nonneoplastic intestinal diseases, Robert E. Petras, intestinal neoplasms, Harry S. Cooper, pancreas, James E. Oertel, Yolanda C. Oertel, and Clara S. Heffess, nonneoplastic liver disease, Dale C. Snover, neoplasms of liver, Scott H. Saul, Gallbladder and estrahepatic biliary tree, Scott H. Saul, anus and perianal area, Donald A. Antoniolo and Henry D. Appleman urinary tract and male genital system female reproductive system and peritoneum. (part contents).

Sister Mary Joseph and Her Nodule: Historical and Clinical Perspective

2009-04-01

Mohannad Abu-Hilal , James S. Newman

Cutaneous metastases in patients with metastatic carcinoma: A retrospective study of 4020 patients

1993-08-01

Donald P. Lookingbill , Nancy Spangler , Klaus F. Helm

Patterns of Cutaneous Metastasis

1972-06-01

Martin H. Brownstein

Patterns of cutaneous metastasis were studied in 724 patients in whom there was histopathologic confirmation of both the primary tumor and the secondary deposit in skin. The most frequent primary … Patterns of cutaneous metastasis were studied in 724 patients in whom there was histopathologic confirmation of both the primary tumor and the secondary deposit in skin. The most frequent primary tumors in men were carcinoma of the lung (24%), carcinoma of the large intestine (19%), melanoma (13%), and squamous cell carcinoma of the oral cavity (12%). The most common primary tumors in women were carcinoma of the breast (69%), carcinoma of the large intestine (9%), melanoma (5%), and carcinoma of the ovary (4%). Metastatic lesions were infrequent on the skin of the lower extremities and common on the anterior part of the trunk. They were recognized before the primary tumor relatively often in carcinoma of the lung and kidney, and rarely in carcinoma of the breast and squamous cell carcinoma of the oral cavity.

Detection of metastasis in cervical lymph nodes: CT and MR criteria and differential diagnosis.

1992-05-01

Peter M. Som

Detection of metastasis in cervical lymph nodes: CT and MR criteria and differential diagnosis.P M SomAudio Available | Share Detection of metastasis in cervical lymph nodes: CT and MR criteria and differential diagnosis.P M SomAudio Available | Share

Donor-Site Morbidity after Harvesting Rib and Iliac Bone

1984-06-01

Simon W. S. Laurie , Leonard B. Kaban , John B. Mulliken +1 more

Laurie, Simon W. S. M.D.; Kaban, Leonard B. D.M.D., M.D.; Mulliken, John B. M.D.; Murray, Joseph E. M.D. Author Information Laurie, Simon W. S. M.D.; Kaban, Leonard B. D.M.D., M.D.; Mulliken, John B. M.D.; Murray, Joseph E. M.D. Author Information

24 The Bone Induction Principle

1967-07-01

Marshall R. Urist , BARRY F. SILVERMAN , KLAS D RING +2 more

URIST, MARSHALL R. M.D.; SILVERMAN, BARRY F. M.D.; DÜRING, KLAS M.D.; DUBUC, FRANCOIS L. M.D.; ROSENBERG, JOEL M. B.S. Author Information URIST, MARSHALL R. M.D.; SILVERMAN, BARRY F. M.D.; DÜRING, KLAS M.D.; DUBUC, FRANCOIS L. M.D.; ROSENBERG, JOEL M. B.S. Author Information

Occult cancer in women with dense breasts: detection with screening US--diagnostic yield and tumor characteristics.

1998-04-01

T M Kolb , Jacob Lichy , Jeffrey H. Newhouse

PURPOSE: To evaluate bilateral screening ultrasound (US) in the detection of otherwise occult masses and cancer in women with dense breasts and normal mammographic and physical examination findings. MATERIALS AND … PURPOSE: To evaluate bilateral screening ultrasound (US) in the detection of otherwise occult masses and cancer in women with dense breasts and normal mammographic and physical examination findings. MATERIALS AND METHODS: Of 11,220 consecutive patients prospectively examined, all 3,626 women with dense breasts and normal mammographic and physical examination findings underwent physician-performed screening US. The size and stage of cancers detected with US alone were compared with those of cancers detected on mammograms, at physical examination, or both, in the remainder of the patients. RESULTS: In the group of 3,626 women, 11 surgically proved cancers in 11 women (prevalence, 0.30%) were identified with US alone. These cancers were not statistically significantly different in mean surgical size and stage from those of 61 nonpalpable, mammographically detected cancers and were smaller and lower in stage than 64 palpable cancers (P < .01) that were diagnosed in the remainder of the population. In the women with dense breasts, overall cancer detection increased by 17% (from 63 to 74 tumors), and the number of tumors detected only with imaging increased by 37% (from 30 to 41 tumors). CONCLUSION: Screening US can depict small, early-stage, otherwise occult cancers similar in size and stage to mammographically identified nonpalpable cancers and smaller and lower in stage than palpable cancers in dense breasts.

Important Advances in Oncology: 1986

1986-07-25

John M. Merrill

These editors must have been taskmasters. They must have held contributors and the publisher to a strict deadline, and the result is that relatively rare commodity—a timely, hardbound book, an … These editors must have been taskmasters. They must have held contributors and the publisher to a strict deadline, and the result is that relatively rare commodity—a timely, hardbound book, an "update text" that is truly new. The volume is handsome enough, with a reasonable price, including even several elegant color plates where black-and-white photography would be useless because of subject matter (in the case of nevi) or less descriptive (in the schematic of chromosomal defects). The text is divided into two parts— basic research and clinical progress— each comprising half the content. There is ample bridging in most chapters. Basic science chapters always note the impact on the clinical sphere, and the clinical chapters demand an awareness of the background science. Overall, the emphasis is clearly toward the clinical. A chapter in the basic research section on the role of dietary fiber in cancer prevention has a very "non-basic science"

Metastatic tumors of the skin

1972-05-01

Martin H. Brownstein , Elson B. Helwig

The clinical and pathologic features of cutaneous metastasis were studied in 724 patients, with histopathologic confirmation of both the primary tumors and the secondary lesions in the skin. Cutaneous metastatic … The clinical and pathologic features of cutaneous metastasis were studied in 724 patients, with histopathologic confirmation of both the primary tumors and the secondary lesions in the skin. Cutaneous metastatic lesions from carcinoma of the lung and kidney were usually found in men, were often recognized before the primary tumor, and appeared in almost every area of the skin surface. Metastasis from carcinoma of the breast to the skin occurred almost exclusively in women, tended to be localized to the anterior chest wall, and was usually found after the primary tumor. Most cutaneous lesions metastasizing from squamous cell carcinoma of the oral cavity were found on the face or neck of men in whom there was previous histologic documentation of the primary tumor.

View PDF Chat

Metastatic tumours to the oral cavity – Pathogenesis and analysis of 673 cases

2007-12-06

Abraham Hirshberg , Anna Shnaiderman-Shapiro , Ilana Kaplan +1 more

Malignant tumors metastatic to mouth and jaws

1965-09-01

Irving Meyer , Gerald Shklar

Textbook of Radiotherapy

1981-01-02

Stanley E. Order

Fletcher's textbook stands as a monument to the extensive clinical development of radiotherapy at M. D. Anderson Hospital, particularly in head and neck and gynecologic malignant disease. The chapter concerning … Fletcher's textbook stands as a monument to the extensive clinical development of radiotherapy at M. D. Anderson Hospital, particularly in head and neck and gynecologic malignant disease. The chapter concerning the basic principles of radiotherapy by Withers and Peters is extensive and well written and covers many of the newer considerations such as hyperthermia, radiation and immunity, immunogenetics, and interaction between radiation and drugs. A well-written and useful chapter concerning dental care in irradiated patients will be welcomed by readers. The review of developments in head and neck radiotherapy is superb. Similarly, an outstanding review is presented by Bouchard of CNS tumors. The thoroughness of Montague's review of breast cancer represents an important experience. A well-written review of lymphomatous disease by Million is as thorough as the pages allow, but one cannot help but feel that the authority of Kaplan would have made this text of finer vintage. Chapters covering

Long-term results of lung metastasectomy: Prognostic analyses based on 5206 cases

1997-01-01

Ugo Pastorino , Marc Buyse , Godehard Friedel +7 more

View PDF Chat

The patterns of cervical lymph node metastases from squamous carcinoma of the oral cavity

1990-07-01

Jatin P. Shah , Frank C. Candela , Anil Poddar

A retrospective review of the records of 501 previously untreated patients from January 1, 1965 through December 31, 1986 with squamous cell carcinoma of the oral cavity was undertaken to … A retrospective review of the records of 501 previously untreated patients from January 1, 1965 through December 31, 1986 with squamous cell carcinoma of the oral cavity was undertaken to ascertain the prevalence of ipsilateral neck node metastases (NM) by neck level. The 501 patients underwent 516 radical neck dissections. Patients were grouped by clinical neck status at the time of neck dissection: elective dissection (ED) in the NO neck, immediate therapeutic dissection (ITD) in the N+ neck, and subsequent therapeutic dissection (STD) in the neck observed which converted clinically to N+. Pathologically identified NM occurred 34% of the time in ED, 69% in ITD and 90% in STD. The sensitivity, specificity, and overall accuracy of the clinical exam was 70%, 65%, and 68%, respectively. Detailed analysis was performed for each group based on the primary site. This revealed a prevalence of NM in level IV of 3% (five of 167) for ED versus 17% (49/ 296) for ITD + STD (P < 0.001). Tongue, retromolar trigone, and cheek did not have NM in level V in any group. The prevalence of NM in level V for floor of mouth or gum primaries was < 1% (one of 109) in ED versus 6% (ten of 167) in ITD + STD (P < 0.03). These data support the trend toward selective limited neck dissection in both NO and N+ patients. Further, they provide the foundation for planning of future prospective trials to assess the efficacy of modifications in the extent of neck dissection.

View PDF Chat

Metastatic patterns in adenocarcinoma

2006-03-03

Kenneth R. Hess , Gauri R. Varadhachary , Sarah H. Taylor +4 more

Abstract BACKGROUND Unique metastatic patterns cited in the literature often arise from anecdotal clinical observations and autopsy reports. The authors analyzed clinical data from a large number of patients with … Abstract BACKGROUND Unique metastatic patterns cited in the literature often arise from anecdotal clinical observations and autopsy reports. The authors analyzed clinical data from a large number of patients with histologically confirmed, distant‐stage adenocarcinoma to evaluate metastatic patterns. METHODS Tumor registry data were collected between 1994‐1996 on 11 primary tumor sites and 15 metastatic sites from 4399 patients. The primary and metastatic sites were cross‐tabulated in various ways to identify patterns, and the authors developed algorithms by using multinomial logistic regression analysis to predict the locations of primary tumors based on metastatic patterns. RESULTS Three primary tumors had single, dominant metastatic sites: ovary to abdominal cavity (91%), prostate to bone (90%), and pancreas to liver (85%). The liver was the dominant metastatic site for gastrointestinal (GI) primary tumors (71% of patients), whereas bone and lung metastases were noted most frequently in non‐GI primary tumors (43% and 29%, respectively). In a study of combinations of liver, abdominal cavity, and bone metastases, 86% of prostate primary tumors had only bone metastases, 80% of ovarian primary tumors had only abdominal cavity metastases, and 74% of pancreas primary tumors had only liver metastases. A single organ was the dominant source of metastases in 7 sites: axillary lymph node from the breast (97%), intestinal lymph node from the colon (84%), thoracic lymph node from the lung (66%), brain from the lung (64%), mediastinal lymph node from the lung (62%), supraclavicular lymph node from the breast (51%), and adrenal gland from the lung (51%). CONCLUSIONS The algorithms that the authors developed achieved a cross‐validated accuracy of 64% and an accuracy of 64% on an 1851‐patient independent test set, compared with 9% accuracy when a random classifier was used. Cancer 2006. © 2006 American Cancer Society.

View PDF Chat

The clinical course of bone metastases from breast cancer

1987-01-01

RE Coleman , RD Rubens

View PDF Chat

Cutaneous metastatic disease

1995-08-01

Robert A. Schwartz

Oral cancer: Clinical features

2010-04-19

José Vicente Bagán Sebastián , Gracia Sarrión , Yolanda Jiménez

A Pooled Analysis of Bone Marrow Micrometastasis in Breast Cancer

2005-08-24

Stephan Braun , Florian D. Vogl , Bjørn Naume +7 more

We assessed the prognostic significance of the presence of micrometastasis in the bone marrow at the time of diagnosis of breast cancer by means of a pooled analysis. We assessed the prognostic significance of the presence of micrometastasis in the bone marrow at the time of diagnosis of breast cancer by means of a pooled analysis.

View PDF Chat

Neoplastic Diseases. A Treatise on Tumors

1941-04-01

James R. Ewing

Neoplastic Diseases. A Treatise on Tumors Get access Neoplastic Diseases. A Treatise On Tumors. Ewing James, A.M., M.D., Sc.D., L.L.D., Professor of Oncology at Cornell University Medical College, New York … Neoplastic Diseases. A Treatise on Tumors Get access Neoplastic Diseases. A Treatise On Tumors. Ewing James, A.M., M.D., Sc.D., L.L.D., Professor of Oncology at Cornell University Medical College, New York City; Consulting Pathologist, Memorial Hospital. Cloth, Ed. 4., 1160 pp., 581 illustrations. $14.00. W. B. Saunders Co., Philadelphia, Pa. American Journal of Clinical Pathology, Volume 11, Issue 4, 1 April 1941, Page 357, https://doi.org/10.1093/ajcp/11.4.357a Published: 01 April 1941

View PDF Chat

Metastases in carcinoma.Analysis of 1000 autopsied cases

1950-01-01

Herbert L. Abrams , Robert Spiro , Norman Goldstein

NE of the most striking and disheartening qualities of cancer is the relentlessness of its spread throughout the organism.At the Montefiore Hospital for Chronic Diseases, the observation was made that … NE of the most striking and disheartening qualities of cancer is the relentlessness of its spread throughout the organism.At the Montefiore Hospital for Chronic Diseases, the observation was made that widespread metastases were present in a higher percentage of the cases that reached the autopsy table than the literature would lead one to believe.Such organs as spleen, ureter, heart-usually considered rare sites of secondary carcinomaappeared to have been involved not uncommonly.Because there have been few recent comprehensive studies of the metastases of carcinoma, it was thought that a study of the metastases of one-thousand consecutive autopsied cases of carcinoma would be of value.

View PDF Chat

Skin involvement as the presenting sign of internal carcinoma

1990-01-01

Donald P. Lookingbill , Nancy Spangler , F. Mack Sexton

Targeting the PDGF signaling pathway in tumor treatment

2013-01-01

Carl‐Henrik Heldin

Platelet-derived growth factor (PDGF) isoforms and PDGF receptors have important functions in the regulation of growth and survival of certain cell types during embryonal development and e.g. tissue repair in … Platelet-derived growth factor (PDGF) isoforms and PDGF receptors have important functions in the regulation of growth and survival of certain cell types during embryonal development and e.g. tissue repair in the adult. Overactivity of PDGF receptor signaling, by overexpression or mutational events, may drive tumor cell growth. In addition, pericytes of the vasculature and fibroblasts and myofibroblasts of the stroma of solid tumors express PDGF receptors, and PDGF stimulation of such cells promotes tumorigenesis. Inhibition of PDGF receptor signaling has proven to useful for the treatment of patients with certain rare tumors. Whether treatment with PDGF/PDGF receptor antagonists will be beneficial for more common malignancies is the subject for ongoing studies.

View PDF Chat

Distribution of metastatic sites in renal cell carcinoma: a population-based analysis

2011-09-04

Marco Bianchi , Maxine Sun , Claudio Jeldres +7 more

Cancer of unknown primary site

2012-03-12

Nicholas Pavlidis , George Pentheroudakis

Detection and Clinical Importance of Micrometastatic Disease

1999-07-07

Klaus Pantel , Richard J. Côté , Øystein Fodstad

Metastatic relapse in patients with solid tumors is caused by systemic preoperative or perioperative dissemination of tumor cells. The presence of individual tumor cells in bone marrow and in peripheral … Metastatic relapse in patients with solid tumors is caused by systemic preoperative or perioperative dissemination of tumor cells. The presence of individual tumor cells in bone marrow and in peripheral blood can be detected by immunologic or molecular methods and is being regarded increasingly as a clinically relevant prognostic factor. Because the goal of adjuvant therapy is the eradication of occult micrometastatic tumor cells before metastatic disease becomes clinically evident, the early detection of micrometastases could identify the patients who are most (and least) likely to benefit from adjuvant therapy. In addition, more sensitive methods for detecting such cells should increase knowledge about the biologic mechanisms of metastasis and improve the diagnosis and treatment of micrometastatic disease. In contrast to solid metastatic tumors, micrometastatic tumor cells are appropriate targets for intravenously applied agents because macromolecules and immunocompetent effector cells should have access to the tumor cells. Because the majority of micrometastatic tumor cells may be nonproliferative (G 0 phase), standard cytotoxic chemotherapies aimed at proliferating cells may be less effective, which might explain, in part, the failure of chemotherapy. Thus, adjuvant therapies that are aimed at dividing and quiescent cells, such as antibody-based therapies, are of considerable interest. From a literature search that used the databases MEDLINE®, CANCERLIT®, Biosis®, Embase®, and SciSearch®, we discuss the current state of research on minimal residual cancer in patients with epithelial tumors and the diagnostic and clinical implications of these findings.

View PDF Chat

Irradiated mammary gland stroma promotes the expression of tumorigenic potential by unirradiated epithelial cells.

2000-03-01

Mary Helen Barcellos‐Hoff , Shraddha A. Ravani

We have shown that ionizing radiation, a known carcinogen of human breast, elicits rapid, persistent, and global changes in the mammary microenvironment as evidenced by altered extracellular matrix composition and … We have shown that ionizing radiation, a known carcinogen of human breast, elicits rapid, persistent, and global changes in the mammary microenvironment as evidenced by altered extracellular matrix composition and growth factor activities. To address whether these events contribute to radiogenic carcinogenesis, we evaluated the effect of irradiated mammary stroma on the neoplastic potential of COMMA-D mammary epithelial cells. Although COMMA-D cells harbor mutations in both alleles of p53, they are nontumorigenic when injected s.c. into syngeneic hosts. Unirradiated COMMA-D cells transplanted to mammary fat pads cleared previously of epithelia preferentially formed tumors in irradiated hosts. Tumor incidence at 6 weeks was 81% +/- 12 SE when animals were irradiated with 4 Gy, 3 days prior to transplantation, compared with 19% +/- 2 SE (P < 0.005) in sham-irradiated hosts. This effect was evident when cells were transplanted 1 to 14 days after irradiation. Furthermore, tumors were significantly larger (243.1 +/- 61.3 mm3 versus 30.8 +/- 8.7 mm3) and arose more quickly (100% by 6 weeks versus 39% over 10 weeks in sham hosts) in fat pads in irradiated hosts. The contribution of local versus systemic effects was evaluated using hemibody (left versus right) irradiation; tumors formed only in fat pads on the irradiated side. These data indicate that radiation-induced changes in the stromal microenvironment can contribute to neoplastic progression in vivo. Disruption of solid tissue interactions is a heretofore unrecognized activity of ionizing radiation as a carcinogen.

Metastatic Patterns of Cancers: Results From a Large Autopsy Study

2008-06-01

Guy diSibio , Samuel W. French

Abstract Context.—Many studies have addressed metastatic patterns seen among various cancers. No recent studies, however, provide quantitative analyses of such patterns arising from a broad range of cancers based primarily … Abstract Context.—Many studies have addressed metastatic patterns seen among various cancers. No recent studies, however, provide quantitative analyses of such patterns arising from a broad range of cancers based primarily on postmortem tissue analyses. Objective.—To provide a quantitative description of metastatic patterns among different primary cancers based on data obtained from a large, focused autopsy study. Design.—Review of data from 3827 autopsies, performed between 1914 and 1943 on patients from 5 affiliated medical centers, comprising 41 different primary cancers and 30 different metastatic sites. Results.—Testicular cancers were most likely to metastasize (5.8 metastases per primary cancer), whereas duodenal cancers were least likely to do so (0.6 metastases per primary cancer). Preferred metastatic sites varied among the primary cancers analyzed. Overall, regional lymph nodes were the most common metastatic target (20.6% of total), whereas testes were the least common (0.1% of total). Conclusions.—Not surprisingly, different primary cancers tended to metastasize, with differing frequencies, to different sites. These varying metastatic patterns might be helpful in deducing the origins of cancers whose primary sites are unclear at presentation.

Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities

2011-05-31

Mario E. Lacouture , Milan J. Anadkat , René‐Jean Bensadoun +5 more

Epidermal growth factor receptor inhibitors (EGFRI) produce various dermatologic side effects in the majority of patients, and guidelines are crucial for the prevention and treatment of these untoward events. The … Epidermal growth factor receptor inhibitors (EGFRI) produce various dermatologic side effects in the majority of patients, and guidelines are crucial for the prevention and treatment of these untoward events. The purpose of this panel was to develop evidence-based recommendations for EGFRI-associated dermatologic toxicities. A multinational, interdisciplinary panel of experts in supportive care in cancer reviewed pertinent studies using established criteria in order to develop first-generation recommendations for EGFRI-associated dermatologic toxicities. Prophylactic and reactive recommendations for papulopustular (acneiform) rash, hair changes, radiation dermatitis, pruritus, mucositis, xerosis/fissures, and paronychia are presented, as well as general dermatologic recommendations when possible. Prevention and management of EGFRI-related dermatologic toxicities is critical to maintain patients’ health-related quality of life and dose intensity of antineoplastic regimens. More rigorous investigation of these toxicities is warranted to improve preventive and treatment strategies.

View PDF Chat

Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2015-08-27

Karim Fizazi , F. Anthony Greco , Nicholas Pavlidis +3 more

Diagnostic and therapeutic management of cancer of an unknown primary

2003-09-01

Nicholas Pavlidis , Evangelos Briasoulis , John D. Hainsworth +1 more

Tumors and Tumorous Conditions of the Bones and Joints. Henry L. Jaffe, M.D. Philadelphia, Lea and Febiger, 1958. $18.50

1958-12-01

Jonathan Cohen

Bone metastasis: the importance of the neighbourhood

2016-05-25

Peter I. Croucher , Michelle M. McDonald , T. John Martin

Sister Mary Joseph's nodule and its relationship to diagnosis of carcinoma of the umbilicus.

1976-08-01

Key Jd , Shephard Da , Waltman Walters

Patterns of metastasis in colon and rectal cancer

2016-07-15

Matias Riihimäki , Akseli Hemminki , Jan Sundquist +1 more

Abstract Investigating epidemiology of metastatic colon and rectal cancer is challenging, because cancer registries seldom record metastatic sites. We used a population based approach to assess metastatic spread in colon … Abstract Investigating epidemiology of metastatic colon and rectal cancer is challenging, because cancer registries seldom record metastatic sites. We used a population based approach to assess metastatic spread in colon and rectal cancers. 49,096 patients with colorectal cancer were identified from the nationwide Swedish Cancer Registry. Metastatic sites were identified from the National Patient Register and Cause of Death Register. Rectal cancer more frequently metastasized into thoracic organs (OR = 2.4) and the nervous system (1.5) and less frequently within the peritoneum (0.3). Mucinous and signet ring adenocarcinomas more frequently metastasized within the peritoneum compared with generic adenocarcinoma (3.8 [colon]/3.2 [rectum]), and less frequently into the liver (0.5/0.6). Lung metastases occurred frequently together with nervous system metastases, whereas peritoneal metastases were often listed with ovarian and pleural metastases. Thoracic metastases are almost as common as liver metastases in rectal cancer patients with a low stage at diagnosis. In colorectal cancer patients with solitary metastases the survival differed between 5 and 19 months depending on T or N stage. Metastatic patterns differ notably between colon and rectal cancers. This knowledge should help clinicians to identify patients in need for extra surveillance and gives insight to further studies on the mechanisms of metastasis.

View PDF Chat

AJCC Cancer Staging Manual

2016-10-24

Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis

2016-09-02

Sebastián Morán , Anna Martínez‐Cardús , Sergi Sayols +7 more

[A pathological report of three COVID-19 cases by minimal invasive autopsies].

2020-05-08

Objective: To investigate the pathological characteristics and the clinical significance of novel coronavirus (2019-nCoV)-infected pneumonia (termed by WHO as coronavirus disease 2019, COVID-19). Methods: Minimally invasive autopsies from lung, heart, … Objective: To investigate the pathological characteristics and the clinical significance of novel coronavirus (2019-nCoV)-infected pneumonia (termed by WHO as coronavirus disease 2019, COVID-19). Methods: Minimally invasive autopsies from lung, heart, kidney, spleen, bone marrow, liver, pancreas, stomach, intestine, thyroid and skin were performed on three patients died of novel coronavirus pneumonia in Chongqing, China. Hematoxylin and eosin staining (HE), transmission electron microcopy, and histochemical staining were performed to investigate the pathological changes of indicated organs or tissues. Immunohistochemical staining was conducted to evaluate the infiltration of immune cells as well as the expression of 2019-nCoV proteins. Real time PCR was carried out to detect the RNA of 2019-nCoV. Results: Various damages were observed in the alveolar structure, with minor serous exudation and fibrin exudation. Hyaline membrane formation was observed in some alveoli. The infiltrated immune cells in alveoli were majorly macrophages and monocytes. Moderate multinucleated giant cells, minimal lymphocytes, eosinophils and neutrophils were also observed. Most of infiltrated lymphocytes were CD4-positive T cells. Significant proliferation of type Ⅱ alveolar epithelia and focal desquamation of alveolar epithelia were also indicated. The blood vessels of alveolar septum were congested, edematous and widened, with modest infiltration of monocytes and lymphocytes. Hyaline thrombi were found in a minority of microvessels. Focal hemorrhage in lung tissue, organization of exudates in some alveolar cavities, and pulmonary interstitial fibrosis were observed. Part of the bronchial epithelia were exfoliated. Coronavirus particles in bronchial mucosal epithelia and type Ⅱ alveolar epithelia were observed under electron microscope. Immunohistochemical staining showed that part of the alveolar epithelia and macrophages were positive for 2019-nCoV antigen. Real time PCR analyses identified positive signals for 2019-nCoV nucleic acid. Decreased numbers of lymphocyte, cell degeneration and necrosis were observed in spleen. Furthermore, degeneration and necrosis of parenchymal cells, formation of hyaline thrombus in small vessels, and pathological changes of chronic diseases were observed in other organs and tissues, while no evidence of coronavirus infection was observed in these organs. Conclusions: The lungs from novel coronavirus pneumonia patients manifest significant pathological lesions, including the alveolar exudative inflammation and interstitial inflammation, alveolar epithelium proliferation and hyaline membrane formation. While the 2019-nCoV is mainly distributed in lung, the infection also involves in the damages of heart, vessels, liver, kidney and other organs. Further studies are warranted to investigate the mechanism underlying pathological changes of this disease.目的：研究新型冠状病毒（2019-nCoV）感染所致新型冠状病毒肺炎（WHO命名为2019冠状病毒病，COVID-19）病理学改变及其临床意义。方法：对重庆地区3例新型冠状病毒肺炎患者进行死亡后微创尸检，获取肺脏、心脏、肾脏、脾脏、骨髓、肝脏、胰腺、胃、肠、甲状腺和皮肤组织。常规HE、透射电镜和组织化学染色观察各脏器组织病理变化，免疫组织化学染色分析炎性细胞浸润情况和2019-nCoV病毒蛋白，荧光定量聚合酶链反应法检测各脏器中2019-nCoV病毒RNA。结果：肺泡结构呈现不同程度的破坏，肺泡腔内见少量浆液和纤维蛋白性渗出物，部分肺泡见透明膜形成。渗出细胞主要为单核细胞和巨噬细胞，可见少数多核巨细胞，淋巴细胞、嗜酸性粒细胞和中性粒细胞。淋巴细胞主要为CD4阳性T细胞。Ⅱ型肺泡上皮细胞显著增生，部分细胞脱落至肺泡腔。肺泡隔血管充血、水肿、增宽，可见少量单核细胞和淋巴细胞浸润，少数微血管内见透明血栓；肺组织灶性出血，部分肺泡腔渗出物机化和肺间质纤维化。肺内各级支气管黏膜均可见部分上皮脱落。电镜下小支气管以下气道黏膜上皮和Ⅱ型肺泡上皮细胞胞质内可见冠状病毒颗粒。免疫组织化学染色显示部分肺泡上皮和巨噬细胞呈2019-nCoV抗原阳性，荧光定量聚合酶链反应检测证实2019-nCoV核酸阳性。脾脏淋巴细胞减少，可见变性、坏死。其他器官组织病变包括不同程度的实质细胞变性、坏死、小血管内透明血栓形成，并见慢性基础疾病改变；均未观测到冠状病毒感染证据。结论：新型冠状病毒肺炎病变以肺最为显著，主要表现为肺泡渗出性炎和间质炎，肺泡上皮细胞增生和透明膜形成，病毒主要分布于肺，但该病还累及免疫器官、心血管、肝脏和肾脏等多个脏器受损。病变机制有待深入研究。.

Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial

2020-06-02

David A. Palma , Robert Olson , Stephen Harrow +7 more

The oligometastatic paradigm hypothesizes that patients with a limited number of metastases may achieve long-term disease control, or even cure, if all sites of disease can be ablated. However, long-term … The oligometastatic paradigm hypothesizes that patients with a limited number of metastases may achieve long-term disease control, or even cure, if all sites of disease can be ablated. However, long-term randomized data that test this paradigm are lacking.We enrolled patients with a controlled primary malignancy and 1-5 metastatic lesions, with all metastases amenable to stereotactic ablative radiotherapy (SABR). We stratified by the number of metastases (1-3 v 4-5) and randomized in a 1:2 ratio between palliative standard-of-care (SOC) treatments (arm 1) and SOC plus SABR (arm 2). We used a randomized phase II screening design with a primary end point of overall survival (OS), using an α of .20 (wherein P < .20 indicates a positive trial). Secondary end points included progression-free survival (PFS), toxicity, and quality of life (QOL). Herein, we present long-term outcomes from the trial.Between 2012 and 2016, 99 patients were randomly assigned at 10 centers internationally. The most common primary tumor types were breast (n = 18), lung (n = 18), colorectal (n = 18), and prostate (n = 16). Median follow-up was 51 months. The 5-year OS rate was 17.7% in arm 1 (95% CI, 6% to 34%) versus 42.3% in arm 2 (95% CI, 28% to 56%; stratified log-rank P = .006). The 5-year PFS rate was not reached in arm 1 (3.2%; 95% CI, 0% to 14% at 4 years with last patient censored) and 17.3% in arm 2 (95% CI, 8% to 30%; P = .001). There were no new grade 2-5 adverse events and no differences in QOL between arms.With extended follow-up, the impact of SABR on OS was larger in magnitude than in the initial analysis and durable over time. There were no new safety signals, and SABR had no detrimental impact on QOL.

View PDF Chat

Handbuch der speziellen pathologischen Anatomie und Histologie.

1926-06-26

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor … Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal

Cancer: Principles and Practice of Oncology

1982-09-03

Walter G. Gunn

A fresh text on general aspects of cancer attempts a great deal: to be comprehensive, to be readable, to be current. The volume at hand seems to fill the bill … A fresh text on general aspects of cancer attempts a great deal: to be comprehensive, to be readable, to be current. The volume at hand seems to fill the bill reasonably well. Its three editors and its associate editors are generally recognized as outstanding workers and clinical researchers in the cancer field; in 49 chapters, the various human cancers are comprehensively analyzed in regard to diagnosis, historical background, etiology, epidemiology, pathology, and details of treatment and prognosis. Some rather "old-hat" topics such as lung cancer have a fresh approach with current material and bibliography. I was pleased to see a detailed section on supportive care of the patient, including nutrition, use of blood products, and management of pain. A short but interesting chapter discusses side effects of treatment—a subject of considerable interest to clinicians and primary care physicians who often must deal with patients and relatives in some misery. Rehabilitation,

EXCISION OF CANCER OF THE HEAD AND NECK.WITH SPECIAL REFERENCE TO THE PLAN OF DISSECTION BASED ON ONE HUNDRED AND THIRTY-TWO OPERATIONS.

1906-12-01

George Crile

Though signal advances have been made recently in many surgical problems, the treatment of cancer of the head and neck has, it would seem, neither received the attention nor kept … Though signal advances have been made recently in many surgical problems, the treatment of cancer of the head and neck has, it would seem, neither received the attention nor kept the pace of progress in other fields. These unhappy cases are too often regarded as specters at the clinic. The operative treatment is hampered by tradition and conventionality, and the tragic ending of so large a proportion of these cases has held back lay and even professional confidence. In this paper it is intended to present an outline sketch of the conclusions regarding the surgical treatment of cancer of the head and neck in the curable stage. The etiology, the diagnosis and the pathology will not be considered. It is generally admitted that cancer is primarily a local disease. Each case, then, is presumably at some period curable by complete excision. The immediate extension from the primary focus is principally

View PDF Chat

Sister Mary Joseph’s Nodule in Gallbladder Carcinoma

2025-06-25

Venkatesh Vaithiyam , Sanjeev Sachdeva , Ravi Teja Reddy +2 more | QJM

Dynamic Mandible Reconstruction Following Disarticulation Tumor Resections: The Hue of Temporofibular Joint

2025-06-24

Ahmed Abdelrehem , Hui Xin Ong , Chao Zhang | International Journal of Oral and Maxillofacial Surgery

Palyatif Kliniklerinde Disiplinlerarası Yaklaşım

2025-06-24

Arzu Nurdaş | Özgür Yayınları eBooks

Palyatif bakım, yaşamı tehdit eden hastalıklarla mücadele eden bireylerin fiziksel, psikolojik, sosyal ve manevi gereksinimlerini bütüncül bir yaklaşımla ele almayı amaçlayan bir sağlık hizmetidir. Bu yaklaşımın etkili bir şekilde uygulanabilmesi … Palyatif bakım, yaşamı tehdit eden hastalıklarla mücadele eden bireylerin fiziksel, psikolojik, sosyal ve manevi gereksinimlerini bütüncül bir yaklaşımla ele almayı amaçlayan bir sağlık hizmetidir. Bu yaklaşımın etkili bir şekilde uygulanabilmesi için farklı sağlık disiplinlerinin birlikte çalışmasını ifade eden disiplinlerarası yaklaşım, palyatif kliniklerde temel bir yapı haline gelmiştir. Hekim, hemşire, psikolog, sosyal hizmet uzmanı, fizyoterapist, diyetisyen ve manevi danışman gibi profesyonellerden oluşan ekipler, hastanın yalnızca tıbbi semptomlarını değil, aynı zamanda duygusal, sosyal ve spiritüel ihtiyaçlarını da göz önünde bulundurarak bakım sunar. Disiplinlerarası yaklaşım, her uzmanlık alanının katkı sunduğu ve ortak karar alma süreçlerinin benimsendiği bir iş birliği modeli oluşturur. Açık iletişim, rol tanımlarının netliği ve ortak hedef bilinci, bu sürecin etkinliğini belirleyen temel unsurlardır. Türkiye’de 2015 yılında Sağlık Bakanlığı tarafından yayımlanan genelge ile palyatif bakım hizmetlerinin disiplinlerarası yapıda sunulması yasal bir çerçeveye kavuşturulmuş, uygulamalar bu doğrultuda şekillenmiştir. Son yıllarda geliştirilen ulusal ve uluslararası kılavuzlar da bu yaklaşımın önemini vurgulamakta, kaliteli palyatif bakımın yalnızca entegre ve iş birliğine dayalı ekip çalışmalarıyla mümkün olabileceğini ortaya koymaktadır. Bu nedenle, palyatif kliniklerde disiplinlerarası yaklaşım, hastaların yaşam kalitesini artırmak ve yaşam sonu süreçlerini daha anlamlı kılmak adına vazgeçilmez bir model olarak öne çıkmaktadır.

Clown Nose-Like Cutaneous Metastasis

2025-06-24

Teng Liu , Jian-Min Chang | British Journal of Dermatology

In this work, we report clown nose-like nodular lesions in a patient with lung carcinoma. Clown nose has been reported to be associated with various malignancies and may present as … In this work, we report clown nose-like nodular lesions in a patient with lung carcinoma. Clown nose has been reported to be associated with various malignancies and may present as the initial manifestation of lung carcinoma. Our work highlights the importance of remaining vigilant for the presence of tumors when nasal lesions resembling a clown nose are observed in clinical practice.

Clinical profile and outcomes of young women with denovo-metastatic breast cancer: real-world data from a tertiary care centre in India

2025-06-24

Sushmita Rath , Mehak Trikha , Laboni Sarkar +7 more | ecancermedicalscience

Denovo metastatic young breast cancer (dnmYBC), defined as age <40 years, is a challenging entity, with a significant burden and sparse data from low and middle-income countries. We analysed the … Denovo metastatic young breast cancer (dnmYBC), defined as age <40 years, is a challenging entity, with a significant burden and sparse data from low and middle-income countries. We analysed the prospectively collected data of dnmYBC women from 2015 to 2016. There were 188 dnmYBC with a median age of 35.5 years. Of these, hormone receptor positive (HR+) were 72 (38.3) %, triple-negatives (TNBC) were 45 (23.9) %, Human Epidermal Growth Factor Positive (HER2+) were 42 (22.4) % and triple positives were 29 (15.4) %. TNBC women predominantly had visceral 40 (88.9%) metastasis, HR+ had nodal 51 (70.8%) and skeletal 10 (13.8%), while HER2+ women had higher brain metastasis (BM) 16 (38.1%).At a median follow-up of 39.8 [Interquartile range (IQR): 24-55.5] months, the median event-free survival (EFS) was 9.3 (95% CI; 8.1-10.4) months for the entire cohort and 1-year, 2-year and 3-year predicted EFS were 47.8%, 13.4% and 3%, respectively. The median EFS was superior in HR+ women.[15.7 months, hormone receptor (HR)-0.53;95% CI-9.8-21.7; p-0.013] versus (11.4 months, 95 %CI-5.9-16.8) in TNBC versus (7.7 months, 95% CI-6.0-9.5) in HER-2 + women and without BM at baseline [9.3 versus 3.0 months (with BM), HR-5.65; CI-1.72-17.9; p-0.001]. Median EFS was superior in the treatment-naïve (155, 82.4%) versus prior-treated (33, 17.5%) women, 35.5 (95% CI:12.24-58.72) versus 12.4 (95% CI:11.45-13.51) months; p-0.000]. The HER2+ women who received targeted therapy in the first line had a significantly superior median EFS of 13.0 versus 7.7 months (HR -0.465:CI 0.22-0.57: p-0.038). Denovo mYBC is associated with an aggressive course, poor prognosticators include HR negative disease, brain metastasis, inadvertent prior treatment and inadequate access to targeted therapies. Early diagnosis, prompt treatment and expanding accessibility are warranted to improve care.

Oral Carcinoma in Atypical Populations: Prognostic Insights in Young Nonsmoking Women Across Middle Eastern Ethnicities

2025-06-24

G. Batshon | International Journal of Oral and Maxillofacial Surgery

Which Factors Facilitate Lung Metastatic Lesion from Head and Neck Cancer: A Single Center Retrospective Analysis

2025-06-24

Lili Cao , Yuan He | International Journal of Oral and Maxillofacial Surgery

The Use of Patient Specific Implants with Condylar Head Preservation following Resection of Tumors in the Mandible

2025-06-24

Joris Geusens | International Journal of Oral and Maxillofacial Surgery

A Rare Case of Metastasis to the Median Lingual Lymph Node in Squamous Cell Carcinoma of the Tongue

2025-06-24

Amer A. Beg , Julia Abdullah , Shehu Abdullahi +5 more | International Journal of Oral and Maxillofacial Surgery

Rare Root of Neck Metastasis of Oral Squamous Cell Carcinoma Postoperatively and A New Reconstructive Method of Large Soft Defects at the Root of the Neck

2025-06-24

Xin Gao , Ning Li , Chuhan Jiang | International Journal of Oral and Maxillofacial Surgery

Deep learning-based hyperspectral technique identifies metastatic lymph nodes in oral squamous cell carcinoma

2025-06-24

Qian Li , Chenyu Guo , Yingyuan Guo | International Journal of Oral and Maxillofacial Surgery

A multicenter retrospective investigation of metastatic tumors in oral and maxillofacial regions.

2025-06-24

Shuhei Yamada | International Journal of Oral and Maxillofacial Surgery

Metastatic Prostate Cancer of the Mandible – A Rare Case Report

2025-06-24

Ravi Kumar Gupta , F. Bridges-Smith , Elshazali Widaa Ali +1 more | International Journal of Oral and Maxillofacial Surgery

Oligometastasierung

2025-06-23

Jürgen Dunst , Thomas Schmidt , Ralf‐Dieter Hofheinz +1 more | Deleted Journal

Metachronous Mediastinal Cancers of Unknown Primary: A Case of Sequential Squamous Cell Carcinoma and Adenocarcinoma in Thoracic Lymph Nodes

2025-06-22

Yasushi Sakamaki , Yuya Kogita , Seigo Minami +4 more | Cureus

Carboplatin/Durvalumab/Paclitaxel

2025-06-21

| Reactions Weekly

Supraclavicular Lymph Node Dissection in Breast Cancer with Synchronous Supraclavicular Metastases: A Systematic Review and Network Meta-Analysis

2025-06-21

George He , Jolene Li Ling Chia , Edgardo S. Santos +5 more | Cancers

Background/Objectives: Synchronous ipsilateral supraclavicular lymph node metastases (sISLMs) in breast cancer are rare and associated with poor prognosis. The optimal locoregional treatment strategy remains unclear, particularly regarding the role of … Background/Objectives: Synchronous ipsilateral supraclavicular lymph node metastases (sISLMs) in breast cancer are rare and associated with poor prognosis. The optimal locoregional treatment strategy remains unclear, particularly regarding the role of supraclavicular lymph node dissection (SLND). Methods: We conducted a systematic review and network meta-analysis, including studies published up to end December 2023, to compare the outcomes of SLND combined with radiotherapy (RT) and systemic therapy (ST), SLND with ST alone, and ST alone, using RT + ST as the reference. Results: Ten studies involving 3346 patients were included for overall survival (OS) analysis, and six studies were included for disease-free survival (DFS). SLND + RT + ST showed similar OS and DFS compared to RT + ST. Sensitivity analyses revealed that SLND limited to level V improved OS (HR: 0.47, 95% CI: 0.29–0.77), while more extensive dissections (level V+) worsened outcomes (HR: 1.41, 95% CI: 1.10–1.80). Conclusions: These findings suggest that selective SLND may benefit certain patients, but broader application should be approached with caution pending results from future randomized trials.

Levothyroxine-sodium

2025-06-21

| Reactions Weekly

Doxorubicin/epinephrine/milrinone

2025-06-21

| Reactions Weekly

Cisplatin/Fluorouracil/Pembrolizumab

2025-06-21

| Reactions Weekly

Magnesium-sulfate/panitumumab

2025-06-21

| Reactions Weekly

Mycophenolate/nintedanib

2025-06-21

| Reactions Weekly

Cancer of Unknown Primary: A Case Report on the Recognition of Its Clinical Entity and Standard of Care Management

2025-06-20

Alexander Lazzaro , Maya Srinivasan , Hussein Assi | Cureus

Cancer of unknown primary (CUP) is a distinct and well-established clinical entity that encompasses a heterogeneous group of histologically proven cancers that present unique diagnostic and therapeutic challenges. This case … Cancer of unknown primary (CUP) is a distinct and well-established clinical entity that encompasses a heterogeneous group of histologically proven cancers that present unique diagnostic and therapeutic challenges. This case describes a male patient in his late 60s who presented with nonspecific gastrointestinal complaints. A comprehensive workup, including clinical evaluation and various biochemical, imaging, and invasive histopathologic tests, led to the diagnosis of CUP following consultation with medical oncology specialists. A decision was made to forgo further invasive molecular tissue sampling in search of a primary malignant process in favor of initiating systemic chemotherapy. The patient possessed an unfavorable set of prognostic signs. Rapid clinical deterioration occurred the day after treatment initiation. A goals of care conversation led to a transition towards comfort measures only care, and the patient ultimately passed away. This case highlights the importance of non-oncologically trained providers recognizing CUP as its own entity to facilitate standard of care management. Future research is needed to establish benefits in clinical trials looking at molecular tumor profiling and site-specific therapies for this rare malignancy.

Metastatic colonic adenocarcinoma presenting in the oral cavity: Disease progression over time

2025-06-20

Moisés Willian Aparecido Gonçalves , Gustavo de Souza Vieira , Nádia Cacita +5 more | Oral Oncology

The clue is on the lip: unmasking esophageal adenocarcinoma: A case report

2025-06-20

Abuoma Cherry Ekpendu , Muhammad Sohaib Asghar , Gregory May +2 more | Medicine

Esophageal cancer accounts for about 1% of all cancer diagnoses in the United States. An 82-year-old male presented to a dermatology clinic with a chief complaint of a skin lesion … Esophageal cancer accounts for about 1% of all cancer diagnoses in the United States. An 82-year-old male presented to a dermatology clinic with a chief complaint of a skin lesion on the right lower lip. He denied any prior gastrointestinal symptoms or history. A shave biopsy of the lip lesion revealed adenocarcinoma. Subsequent positron emission tomography-computed tomography demonstrated findings concerning for esophageal malignancy with metastatic disease. Esophagogastroduodenoscopy identified a lesion in the distal esophagus, and biopsy confirmed invasive, moderately to poorly differentiated esophageal adenocarcinoma. The patient was referred to oncology, where he was diagnosed with stage IV metastatic esophageal adenocarcinoma. He was initiated on chemotherapy, which he tolerated well. This case highlights the rare presentation of stage IV esophageal adenocarcinoma as a solitary lip lesion without typical gastrointestinal symptoms. Given the rarity of lip involvement, clinicians should maintain a high index of suspicion for systemic malignancy in atypical skin lesions. Early biopsy and diagnosis are crucial for timely intervention and improved outcomes. The purpose of the study is to highlight the importance of maintaining a high index of suspicion for gastrointestinal malignancy, even in the absence of traditional gastrointestinal symptoms, when evaluating unusual skin lesions.

Muscle Metastasis as an Atypical Presentation of Non-small Cell Lung Cancer: A Case Report and Literature Review

2025-06-19

Fatima Rezzoug , Jihane Derfoufi , Ouissam Al Jarroudi +2 more | Cureus

Isolated Pancreatic Metastasis from Esophageal Squamous Cell Carcinoma: A Rare Case Report with Review of Literature

2025-06-19

Pranjal Banthia , Sandeep Bhoriwal , Amitabha Mandal +1 more | Indian Journal of Surgery

Thyroid nodule - ACR TI-RADS 5

2025-06-19

Henry Knipe | Radiopaedia.org

Beyin Metastazı için Gamma Knife Radyocerrahisi ile Tedavi Edilen Hastalarda Likit Biyopsinin Rolü

2025-06-19

Büşra Karaçam , Imran Khan , Elif Burce Elbasan +3 more | Sağlık Bilimlerinde İleri Araştırmalar Dergisi / Journal of Advanced Research in Health Sciences

Pancreatic metastasis from renal cell carcinoma

2025-06-18

Ammar Ashraf | Radiopaedia.org

Double Jeopardy: Gastric Carcinoma Masquerading as Acute Limb Ischaemia

2025-06-17

Tammiraju Iragavarapu , S. Ayyar , N. V. Ramnadh +1 more | Indian Journal of Surgical Oncology

Cutaneous Presentations of Metastatic Carcinoma Breast: A Case Series

2025-06-17

Sonal Mandli , Ashma Surani , Yashika Jayesh Doshi +1 more | Indian Dermatology Online Journal

Abstract Skin is an outer reflection of our overall health. Cutaneous metastases occur due to the persistence or recurrence of primary solid tumors. It occurs in 0.7 to 10.4% of … Abstract Skin is an outer reflection of our overall health. Cutaneous metastases occur due to the persistence or recurrence of primary solid tumors. It occurs in 0.7 to 10.4% of all patients diagnosed with cancer, although they represent only 2% of all skin tumors. Cutaneous metastasis from breast carcinoma has varied presentations with different morphologies and appearances. It presents as red, firm papules, nodules, or plaques with either smooth, crusted, or ulcerated surfaces over ipsilateral chest wall. However, it can occur at some unusual sites like the scalp, eyelids, inframammary area, arms, umbilicus, nails, and mastectomy scar. Skin lesions of breast cancer metastases can be confused with some benign cutaneous lesions (cysts, dermatofibroma), skin malignancies (melanoma and non-melanoma skin cancers), infections (folliculitis, pyoderma, erysipelas, herpes zoster), dermatological conditions (dermatitis, hidradenitis suppurativa), reactive erythemas (urticaria, insect bite hypersensitivity), and vascular conditions (petechiae, purpura, pyogenic granuloma, angiosarcoma). Carcinoma en cuirasse, carcinoma erysipeloides, carcinoma telangiectoides, and carcinoma hemorrhagiectoides are various patterns of skin metastases. Concerning morphology and appearance, a dermatologist should have adequate knowledge to recognize and evaluate such patients, with or without a history of breast cancer, for early detection of metastasis and further treatment. Here, we report a case series of 10 patients with diverse appearances of metastatic breast cancer that could mimic other dermatological conditions.

A case of sternal metastasis caused by renal clear cell carcinoma

2025-06-16

Zhe Wang , Chengfang Yu , Yilan Piao | Medical Ultrasonography

. .

Abstract P3-02-01: Is Autologous Fat Grafting a Safe Option or a Risk of Cancer Recurrence in Women with Breast Cancer Who Carry Germline Pathogenic Variants?

2025-06-13

Lucrezia Raimondi , C Schumacher , Barbara Veronese +7 more | Clinical Cancer Research

Abstract Background: Autologous fat grafting (lipofilling, LF) is widely accepted for breast reconstruction after cancer surgery (breast conservative treatment and mastectomy), due to its potential to improve aesthetic outcome. However, … Abstract Background: Autologous fat grafting (lipofilling, LF) is widely accepted for breast reconstruction after cancer surgery (breast conservative treatment and mastectomy), due to its potential to improve aesthetic outcome. However, its long-term oncological safety in breast cancer patients with pathogenic germline variants (gPV) is still not well documented. This study aims to compare the incidence of local recurrence in breast cancer (BC) patients with gPV who underwent LF compared to those who received breast reconstruction without LF. Methods: A retrospective, single-center, case-control study has been conducted, including BC women with gPV referred to the High Cancer Risk Clinic in southern Switzerland who underwent surgery followed by breast reconstruction with or without LF. Autologous fat was aspirated using a standard tumescent solution, yet neither centrifuged nor enriched. Patient demographic details, clinical information, reconstruction procedures, and fat grafting data were systematically collected. Results: Among 897 women with BC referred for genetic counselling and testing, 132 carried heterozygous gPVs in the following genes: 44 (33%) in BRCA1, 39 (30%) in BRCA2, 1 (1%) in BRCA1 and BRCA2, 10 (8%) in CHEK2, 4 (3%) in PALB2, 8 (6%) in ATM, 1 (1%) in CDH1, 1 (1%) in PTEN, 3 (2%) in BRIP1, 3 (2%) in NTLH1, 2 (2%) in RAD51C, 2 (2%) in NBN and 1 (1%) in TP53. In addition, variants were identified in other cancer predisposition genes based on family history: 3 (2%) in MUTHY, 1 (1%) in CDKN2A, 2 (2%) in PMS2, 4 (3%) in CFTR, 1 (1%) in MSH6, 1 (1%) in MITF and 1 (1%) in SDHA. The median age at cancer diagnosis was 42 years (range: 21-82). Out of the women included in the study, 54% underwent mastectomy, while the remaining 46% opted for breast-conserving surgery. A total of 25 LF procedures were performed, with an average of 2 sessions per patient (range: 1-4). Median follow-up was 84 months from the primary surgery (range: 12-408 months) and 36 months from the LF (range: 12-84 months). Thirty-seven cases of locoregional recurrence were observed, including 1 (4%, a BRCA1 triple-negative breast cancer not associated with ductal intraepithelial neoplasia) in the LF group and 36 (33.6%) in the no-LF group. Fourteen of these patients underwent mastectomy, and four had contralateral prophylactic mastectomy. For this group of patients, the results of the genetic tests were distributed as follows: 14 for BRCA1, 12 for BRCA2, 2 for ATM, 3 for CHEK2, 2 for MUTYH, 1 for NTLH1, 1 for NBN, 1 for PALB2 and 1 for TP53. Conclusions: The current evidence does not support the opinion that the use of LF in reconstruction following mastectomy or conservative surgery in gPV carriers with BC significantly increases the risk of locoregional recurrence. Citation Format: Lucrezia Raimondi, Cora Schumacher, Barbara Veronese, Pasquale Buonandi, Rosaria Condorelli, Elena Trevisi, Lorenzo Rossi, Corrado Parodi, Daniel Schmauss, Yves Harder, Simone Schiaffino, Nickolas Peradze, Rossella Graffeo Galbiati. Is Autologous Fat Grafting a Safe Option or a Risk of Cancer Recurrence in Women with Breast Cancer Who Carry Germline Pathogenic Variants? [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2024; 2024 Dec 10-13; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2025;31(12 Suppl):Abstract nr P3-02-01.

Abstract P5-12-13: Does Ductal Carcinoma in Situ have metastatic potential? A nationwide cancer registry-based study of Ductal Carcinoma in Situ with sentinel lymph node positivity

2025-06-13

M. van Leeuwen , Sandra van den Belt-Dusebout , Petra Kristel +5 more | Clinical Cancer Research

Abstract Background: The current clinical paradigm around Ductal Carcinoma in Situ (DCIS) is that it consists of malignant cells confined to the breast ducts, and therefore cannot metastasize. Nonetheless, several … Abstract Background: The current clinical paradigm around Ductal Carcinoma in Situ (DCIS) is that it consists of malignant cells confined to the breast ducts, and therefore cannot metastasize. Nonetheless, several studies have reported DCIS with metastasis in the sentinel lymph node. For accurate risk communication and management, we aimed to assess to what extent registered “metastatic spread” in DCIS could be explained by limitations in registration or missed invasive breast cancer at time of diagnosis. Methods: Nationwide data on women diagnosed with DCIS and a positive sentinel node (DCIS SN+) between 2005 and 2021 were obtained from the Netherlands Cancer Registry (NCR) and the Dutch Nationwide Pathology Databank (Palga). The incidence of registered DCIS SN+ and the size of the metastasis was determined with data from NCR. Pathology data of the primary DCIS diagnosis was thoroughly reviewed, with all known corresponding history pathology reports of in-situ or invasive breast cancer or unknown primary. Cases were excluded from further analysis if PALGA data indicated registration errors, DCIS mixed with other types of lesions, or diagnostic uncertainties such as suspicion of microinvasion, uncertain sentinel node status, poor tissue quality or positive surgical margins. Next, hematoxylin and eosin stained tissue slides of eligible DCIS SN+ cases were independently reviewed by two expert breast pathologists to assess the presence of (micro)invasion and sentinel node status. Presence of invasion and sentinel node positivity was scored as yes, uncertain, no or not applicable. For cases scored as uncertain, additional immunohistochemical (IHC) stainings with cytokeratin 5/6 or 8/18 were used. Agreement between the two pathologists was assessed using the linearly weighted Kappa statistic. Results: A total of 30,863 patients were identified with a DCIS diagnosis between 2005 and 2020, of which 16,070 (52.1%) underwent sentinel lymph node biopsy according to NCR data. SN+ was identified in 454 (2.8 %) patients: 47 (10 %) had macrometastases (&gt;2 mm), 78 (17%) had micrometastases (&gt;0.2 - &lt;= 2 mm), and 329 (73%) were positive for isolated tumor cells (ITCs) (&lt;= 0.2 mm). Out of the 454 registered DCIS SN+ cases, 273 (60%) were excluded from further investigation based on pathology data from Palga, based on registration errors (n=44), due to the presence of other lesions (n=147), or diagnostic uncertainties (n=82). There was no significant difference in reasons for exclusion between micrometastases, macrometastases or ITCs (p = 0.36). Tissue material of 47 out of 181 DCIS cases with macro- and micrometastases were reviewed by the pathologists. Initial agreement on sentinel node status was weak with a kappa statistic of 0.33 (95% CI 0.15 – 0.52; p = 0.003. Agreement on the presence of an invasive component was minimal with a kappa statistic of 0.14 (95% CI 0.08 – 0.34 ; p = 0.12). The most frequent discrepancies were between ‘uncertain’ and ‘no’ scorings. After reaching consensus, three cases were scored as having an invasive component, and additional IHC staining was requested for 40 cases due to suspicion of the presence of (micro)invasion. Review results of these 40 cases will be presented at the conference. Conclusions: Our study offers a nuanced understanding of DCIS SN+ cases, suggesting that while these cases pose diagnostic challenges, the metastatic potential of pure DCIS remains low. Citation Format: Merle van Leeuwen, Sandra van den Belt-Dusebout, Petra Kristel, Lennart Mulder, Joyce Sanders, Carmen Vlahu, Esther Lips, Jelle Wesseling. Does Ductal Carcinoma in Situ have metastatic potential? A nationwide cancer registry-based study of Ductal Carcinoma in Situ with sentinel lymph node positivity [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2024; 2024 Dec 10-13; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2025;31(12 Suppl):Abstract nr P5-12-13.

Abstract P1-03-08: Clinico-pathological Characteristics of Breast Invasive Lobular Carcinoma in non-CDH1 genetic predisposition. Experience from the Institut Curie.

2025-06-13

Lounes Djerroudi , Rigleta Brahimaj , Chrystelle Colas +7 more | Clinical Cancer Research

Abstract Background: Invasive lobular carcinomas (ILC) represent 15% of breast cancers and are characterized by inactivation of E-cadherin (encoded by the CDH1 gene). Hereditary ILCs are rare and may be … Abstract Background: Invasive lobular carcinomas (ILC) represent 15% of breast cancers and are characterized by inactivation of E-cadherin (encoded by the CDH1 gene). Hereditary ILCs are rare and may be linked to germline mutations in CDH1, or to other genes (including BRCA2 and PALB2). The clinical and histopathological features of hereditary ILC unrelated to CDH1 mutation remain poorly described in the literature to date. Materials and Methods: A retrospective series of ILC diagnosed in a context of constitutional genetic predisposition unrelated to CDH1 was retrospectively identified within Institut Curie's department of Genetics database. The selection criteria were patients with ILC and a pathogenic or likely pathogenic germline mutation in genes other than CDH1 over the period 2020 to 2023. The following data were collected from the electronic patient record: mutated gene associated with hereditary breast cancer predisposition, patient age at ILC diagnosis, bilaterality, occurrence of other cancers, histological type, grade, hormone receptor (HR), and HER2 status. Results: Seventeen patients with BRCA1 mutations, 80 with BRCA2 mutations and 12 with PALB2 mutations were identified. ILC was the first cancer diagnosed in almost all patients (13/14 [93%] for BRCA1, 55/59 [93.2%] for BRCA2 and 8/10 [80%] for PALB2). Patients were index cases in 75% (9/12) for BRCA1, 63.6% (35/55) for BRCA2 and 57.1% (4/7) for PALB2. The mean age at diagnosis was 42.1, 45.9 and 49.3 years, respectively for patients with BRCA1, BRCA2 and PALB2 mutation. The occurrence of bilateral disease at diagnosis was not common (0/9 [0%] for BRCA1, 6/57 [10.5%] for BRCA2, and 1/8 [12.5%] for PALB2). BRCA2- and PALB2-related cases exhibited mainly grade 1-2 (46/62 [74.1%] for BRCA2, and 8/10 [80%] for PALB2), and HR-positive ILCs (55/59 [93.2%] for BRCA2, and 8/8 [100%] for PALB2). In BRCA1-mutated patients, ILCs were enriched in grade 3 (5/13 [38.4%]) and HR-negative phenotype (4/12 [33.3%]). The prevalence of HER2-positive status was found to be slightly higher among patients with BRCA1 and PALB2 mutations (1/10 [10%] and 1/9 [11.1%], respectively) in comparison to those with a BRCA2 mutation (3/51 [5.8%]). Conclusion: ILCs diagnosed in the context of a germline BRCA1, BRCA2 or PALB2 mutation occured at a younger age than sporadic ILCs. Hereditary BRCA2- and PALB2-related ILCs exhibit histo-phenotypical features comparable to sporadic tumors (predominantly grade 1-2, HR-negative, HER2-negative). Interestingly, ILCs associated with germline BRCA1 mutations appear to have a distinct phenotype in our series (enriched for grade 3 and HR-negative status), although this gene has not yet been identified as a predisposing factor for ILC. Citation Format: Lounes Djerroudi, Rigleta Brahimaj, Chrystelle Colas, Victoire Montecalvo, Lisa Golmard, Claire Saule, Bruno Buecher, Hélène Delhomelle, Jessica Le Gall, Mathilde Warcoin, Mélanie Pagès, Nicolas Pouget, Fabien Reyal, Caroline Malhaire, Youlia Kirova, Dominique Stoppa-Lyonnet, Emmanuelle Mouret-Fourme, Anne Vincent-Salomon. Clinico-pathological Characteristics of Breast Invasive Lobular Carcinoma in non-CDH1 genetic predisposition. Experience from the Institut Curie [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2024; 2024 Dec 10-13; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2025;31(12 Suppl):Abstract nr P1-03-08.

Abstract P4-03-11: Patient and health care provider perspectives on oral versus intramuscular endocrine therapy for locally advanced or metastatic breast cancer

2025-06-13

Rebecca M. Speck , Spencer Schaff , Gale Harding +7 more | Clinical Cancer Research

Abstract Background: Next generation oral selective ER degraders (SERDs) have been designed to improve efficacy and tolerability and may serve as an alternative to intramuscular (IM) fulvestrant for the treatment … Abstract Background: Next generation oral selective ER degraders (SERDs) have been designed to improve efficacy and tolerability and may serve as an alternative to intramuscular (IM) fulvestrant for the treatment of ER+, HER2- locally advanced or metastatic breast cancer (MBC). Thus, it is important to understand perspectives on the benefit and burden of oral and IM endocrine therapy (ET) from both patients and health care providers (HCPs). Methods: This US-based qualitative interview study recruited female patients with MBC treated with both oral ET and fulvestrant within the past 3 years and HCPs (medical oncologists and oncology nurses). One-on-one semi-structured interviews focused on four concepts: preference, benefits, burdens, and adherence to oral and IM ET. Patients spoke directly about their own personal experience with both types of administration, while HCPs provided their perspectives based on their clinical practice experience. Interviews were conducted by a third-party vendor and occurred September 2023 through May 2024. Interview transcripts were analyzed in ATLAS.ti through an iterative process and followed a qualitative analysis plan. Results: An asterisk is used to denote responses that are not mutually exclusive. Of the 22 patients interviewed, 64% preferred oral ET, 27% preferred IM ET, and 9% had no preference. Of the fourteen patients that preferred oral ET, they did so for convenience (71%)*, non-painful administration (36%)*, and fear of needles (21%)*. Six patients preferred IM ET due to ease of monthly administration. The benefit of oral ET reported by the greatest proportion of patients was convenience (86%)*, followed by belief that the treatment is working (32%)*. The benefit reported by the greatest proportion of patients for IM ET was belief that the treatment is working (64%)*, followed by not having to remember to take it (36%)*. Patient reported burdens to oral ET included side effects (59%)*, remembering to take medication (32%)*, insurance (23%)*, and reminder of diagnosis (18%)*. Patient-experienced burdens to IM ET were injection site pain (91%)*, side effects (82%)*, and having to travel for monthly appointments (45%)*. Nearly all patients (91%)* reported it was easy to take their oral ET, whereas 32%* reported it was easy to receive the IM ET. Of the 20 HCPs interviewed (medical oncologists=10, oncology nurses=10), nearly all (90%) perceived patients to prefer oral ET. All HCPs stated patient convenience is a benefit of oral ET, and patients not having to remember to take medication is a benefit of IM ET. HCPs also reported inadequate insurance coverage (55%)*, side effects (40%)*, and compliance (30%)* to be perceived burdens of oral ET, and that pain (85%)* and travel (70%)* were burdens of IM ET. HCPs’ perception of ease of administration was equivalent for both oral and IM ET, 80% reporting they were both easy. Conclusion: Among patients with MBC that have been treated with both oral and IM ET, the majority prefer oral ET and report that convenience of an orally administered medication was considered a key benefit and the leading reason for preference of oral ET. Injection site pain and the need to travel for monthly appointments for IM ET were reported burdens from patients and perceived as burdens from HCPs. Notably, although most HCPs reported ease of administration for both oral and IM ET, only a third of patients interviewed reported that it was easy to receive IM ET. Citation Format: Rebecca Speck, Spencer Schaff, Gale Harding, Nalin Payakachat, Jincy John, Aarti Chawla, Christine Agius, Shakeela W Bahadur, Kathryn E Hudson, Mohammed Jaloudi, Ritesh Parajuli, Gregory A Vidal, Elizabeth D Bacci. Patient and health care provider perspectives on oral versus intramuscular endocrine therapy for locally advanced or metastatic breast cancer [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2024; 2024 Dec 10-13; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2025;31(12 Suppl):Abstract nr P4-03-11.

Abstract PS18-09: Endocrine Response in Women with Invasive Lobular Carcinoma (TBCRC 037): A Multicenter Randomized Clinical Trial

2025-06-13

Priscilla F. McAuliffe , Clark BZ , Hieken TJ +7 more | Clinical Cancer Research

Abstract Background: Adjuvant endocrine therapy (ET) recommendations for patients (pts) with invasive lobular carcinoma (ILC) are no different than for other breast cancer subtypes. However, due to unique differences in … Abstract Background: Adjuvant endocrine therapy (ET) recommendations for patients (pts) with invasive lobular carcinoma (ILC) are no different than for other breast cancer subtypes. However, due to unique differences in estrogen pathway signaling of ILC, identifying biological markers of ET sensitivity or resistance could have a major impact on its clinical management. Pre-clinical studies suggest that fulvestrant may be more effective than anastrozole or tamoxifen for ILC. Here we test reduction in the proliferation marker Ki67 as a surrogate for treatment response to ET. Methods: This open label, randomized, controlled, multicenter phase 0 window of opportunity trial (NCT02206984) was conducted at 12 TBCRC institutions between 10/8/15 and 7/28/23. Postmenopausal women with previously untreated hormone receptor-positive (HR+), HER2 negative ILC, centrally histologically confirmed on diagnostic core needle biopsy (CNB), measuring ≥ 1 cm, were eligible. Stage IV was excluded. Pts were randomized 1:1:1 to fulvestrant (500 mg IM on days 1 and 15), anastrozole (1mg/day) or tamoxifen (20 mg/day). After 21-27 days of treatment, pts underwent operation (from which a CNB of residual tumor bed was taken) or a post-treatment image-guided CNB. The primary endpoint was change in Ki67 immunohistochemistry at post-treatment compared to baseline. Given the log-normal distribution of Ki67 measurements generally observed in this population, values were log-transformed for statistical analysis [log (post/pre)]. Group medians were compared using a quantile regression linear model adjusting for institutional-level random effects. A linear mixed model (glmmTMB R package) was fit that allowed for treatment level error variance. Post-hoc pairwise comparison of log(post/pre) were performed using Tukey adjustment for multiple comparison. Results: 201 women were randomized, 172 completed the assigned treatment, and 138 (fulvestrant n=37; anastrozole n=49; tamoxifen n=52) had evaluable pre- and post-treatment tissue. No serious adverse events or deaths occurred. Pre-treatment demographic and tumor characteristics were well-balanced between the treatment groups. Median [range] age was 67 [48-86] years. Race was reported as Asian in 2 (1.5%), Black in 15 (10.9%), other in 4 (2.9%) and White in 117 (84.8%). Presenting clinical stage was IA in 54 (39.1%), IB in 4 (2.9%), IIA in 51 (37%), IIB in 19 (13.7%), IIIA in 4 (2.9%), IIIB in 5 (3.6%), and IIIC in 1 (0.7%). Median H-score [IQR] was ER 260 [50], PR 140 [215]. In the fulvestrant, anastrozole and tamoxifen groups respectively, pre-treatment Ki67 [IQR] was 13.8 [13.5], 13.6 [8.7], and 12.6 [11.9]; and post-treatment Ki67 [IQR] was 4.8 [5.4], 4.5 [5.6], and 5.7 [10]. A statistically significant reduction in Ki67 was found favoring fulvestrant vs tamoxifen (p=0.0419). No significant difference after adjustment was seen between anastrozole and tamoxifen (p = 0.2602) or between fulvestrant and anastrozole (p = 0.6643). Conclusions: A greater reduction in Ki67 was seen post-treatment in CNB of pts with ILC treated with fulvestrant vs tamoxifen. Interestingly, tamoxifen treatment resulted in a reduction in Ki67 of a similar magnitude to anastrozole, despite clinical concerns about its reduced efficacy in ILC. Planned correlative studies will determine whether Ki67 reduction is associated with alterations in expression of ER and ER-regulated genes and/or in other novel pathways, potentially opening avenues for improved treatment strategies in ILC. Citation Format: Priscilla McAuliffe, Clark BZ, Hieken TJ, Mukhtar RA, Linden H, Nangia J, Gallagher K, Stringer-Reasor E, Bedrosian I, Feldman S, Nanda R, Boisvert M, Rothman J, Sikora MJ, Atkinson JM, Thorpe H, Tatsuoka C, Lee AV, Thompson A, Davidson NE, Oesterreich S, Jankowitz RC; on behalf of the Translational Breast Cancer Research Consortium (TBCRC). Endocrine Response in Women with Invasive Lobular Carcinoma (TBCRC 037): A Multicenter Randomized Clinical Trial [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2024; 2024 Dec 10-13; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2025;31(12 Suppl):Abstract nr PS18-09.

Revisión sistemática del colgajo miocutáneo de platisma en la reconstrucción de cáncer oral

2025-06-13

María San Millán-González , Luis Miguel Torres-Morientes , Marta Alonso-Mesonero +1 more | Revista ORL

Introducción y objetivo: La reconstrucción de la cavidad oral requiere técnicas eficaces para restaurar la función y la estética; esta revisión evalúa los resultados de los colgajos miocutáneos de platisma … Introducción y objetivo: La reconstrucción de la cavidad oral requiere técnicas eficaces para restaurar la función y la estética; esta revisión evalúa los resultados de los colgajos miocutáneos de platisma (PMF). Método: Se realizó una revisión sistemática con enfoque de síntesis narrativa, analizando resultados clínicos de estudios primarios, utilizando las bases de datos PubMed, Embase y Scopus. La búsqueda incluyó términos como «platysmal flap», «oral cancer», «reconstruction», y «clinical outcomes», centrada en estudios sobre colgajos miocutáneos de platisma para carcinoma escamoso bucal. Se consideraron artículos en todos los idiomas, excluyendo aquellos enfocados en técnicas experimentales o alternativas de colgajos. La evaluación del riesgo de sesgo se llevó a cabo mediante la herramienta ROBINS-I. Resultados: Los colgajos PMF y locales lograron altas tasas de éxito en función y estética; entre el 73 % y el 82 % de los pacientes recuperaron la ingesta oral normal y el habla. Complicaciones como la necrosis parcial (6.7–10 %) se manejaron de forma conservadora. Discusión: Los PMF resultan ser una solución versátil y eficiente en tiempo para defectos intraorales, especialmente en entornos donde la transferencia de tejido libre no es viable; los mejores resultados se observaron en defectos pequeños. Conclusiones: Los colgajos regionales, especialmente los PMF, son efectivos y prácticos para la reconstrucción de la cavidad oral, ofreciendo una excelente recuperación funcional, resultados estéticos y mejoras en la calidad de vida, con tasas de complicaciones manejables.

Global bone cancer incidence and death rate analysis at 40 years

2025-06-13

Peiran Liu , Hang Lv , Yongji Li +3 more | Discover Oncology

Metastatic Gallbladder Cancer Presenting as Forearm Pain with Radial Bone Metastasis

2025-06-13

Aashita , Pragyat Thakur , Vikas Yadav +1 more | Journal of Medical Sciences

Abstract Gallbladder cancer (GBC) is a relatively rare cancer associated with poor prognosis due to early direct invasion of adjacent structures and nodal metastasis. Isolated bone metastasis is rarely reported … Abstract Gallbladder cancer (GBC) is a relatively rare cancer associated with poor prognosis due to early direct invasion of adjacent structures and nodal metastasis. Isolated bone metastasis is rarely reported and only a few cases are available in literature. A 42-year-old female presented with forearm pain and mass for 3 months duration. She had undergone open cholecystectomy 4 years ago for cholelithiasis. Excision biopsy with decompression of posterior interosseous nerve showed metastatic adenocarcinoma deposit in bone. Fludeoxyglucose (FDG) avid soft-tissue thickening in postoperative bed along with FDG avid cortical erosion in the left occipital bone and lytic sclerotic lesion in left proximal radius was noted. The patient was started on palliative chemotherapy with gemcitabine and cisplatin. Diagnosis with GBC portends dismal prognosis due to local spread and distant metastasis. Metastasis is common to the liver and regional nodes. Isolated bone metastasis is extremely rare.

From Aesthetic to Alarming: Ductal Carcinoma In Situ Following Breast Fat Grafting

2025-06-13

Laila Ashkar , Bashair M Abufarea , Fai F Alkaeid +2 more | Cureus

Abstract P3-07-07: 10-Year Local Recurrence Rates Following Selective Omission of Re-excision for Patients with Ductal Carcinoma in Situ and Margins

2025-06-13

Cecily Stockley , Shahram Bahmanyar , Yuan Xu +3 more | Clinical Cancer Research

Abstract Background: Current guidelines recommend ≥2mm margins for ductal carcinoma in situ (DCIS) with or without microinvasion to optimize local control following breast conserving surgery (BCS). There is some evidence … Abstract Background: Current guidelines recommend ≥2mm margins for ductal carcinoma in situ (DCIS) with or without microinvasion to optimize local control following breast conserving surgery (BCS). There is some evidence to suggest it is acceptable to omit re-excision for “close” margins (i.e. not on-ink but &lt;2mm), particularly when radiation therapy (RT) is planned. This study evaluates 10-year local recurrence (LR) rates following selective omission of re-excision in patients with DCIS and margins &lt;2mm. Methods: We conducted a retrospective population-based cohort study on patients undergoing BCS for DCIS with or without microinvasion from 2010-2014 in the province of Alberta. Final margin status was categorized as on-ink, &lt;1mm, 1-1.9mm and ≥2mm. Given small sample size with on-ink margins, these were included with the &lt;1mm group for analysis. As per provincial guidelines, use of RT boost was recommended for margins &lt;2mm. The primary outcome was local recurrence of in situ or invasive disease in the ipsilateral breast. We generated Kaplan Meier curves and performed Cox proportional hazards analysis to evaluate the effect of margin status on LR. We used an interaction test to determine if the effect of margin status differed by RT use. Results: 468 patients underwent BCS for DCIS with a median age of 59 years (IQR: 50.5-66). The majority were unifocal (n=409, 87.4%) with pure DCIS without microinvasion (n=424, 90.6%), and 51.5% (n=241) had grade 3 disease. Hormone receptor testing was not routine, but among tested patients, 88.9% were estrogen receptor (ER)-positive. The re-excision rate was 23.9% (n=112). Final margin status was on-ink in 13 (2.8%) patients, &lt;1mm in 39 (8.3%), 1-1.9mm in 37 (7.9%) and ≥2mm in 379 (81.0%). Among those 89 patients with margins &lt;2mm, most (94.4%) had only a single margin location &lt;2mm. In 36 (40.4%) patients, the only margin that was &lt;2mm was in the anterior or posterior location, and thus re-excision may not have been feasible. The majority (n=390, 83.3%) had adjuvant RT, whereas adjuvant endocrine therapy (ET) use was infrequent (n=43, 9.2%). The only clinical characteristic that differed for patients with &lt;2mm vs. ≥2mm margins was proportion of multifocality (20.2 vs. 10.8%, p=0.02). Otherwise, there was no significant differences in age, grade, pure DCIS vs. microinvasion, ER status, RT use (82.9% vs. 83.8%) or ET use (all p&gt;0.05), including when those with only anterior/posterior margins &lt;2mm were excluded from the &lt;2mm group. Median follow-up was 10.9 years (IQR: 9.8-12.3). 10-year rates of LR by final margin width were as follows: 23.0% (95%CI: 13.1-38.6) for &lt;1mm, 8.8% (95%CI: 2.9-24.9%) for 1-1.9mm and 5.9% (95%CI: 3.9-8.9%) for ≥2mm (log-rank p&lt;0.001). In Cox proportional hazards analysis, margins &lt;1mm were associated with significantly higher risk of LR compared to margins ≥2mm (HR 4.22, p&lt;0.001), while margins 1-1.9mm were not (HR 1.35, p=0.62). Results were unchanged when adjusting for multifocality (adjusted HR for &lt;1mm margins = 4.16, p&lt;0.001; adjusted HR for 1-1.9mm margins = 1.25, p=0.72), and also when those with only anterior/posterior margins &lt;2mm were excluded from the &lt;2mm groups. There was no statistically significant interaction between margin status and RT use (p=0.52), though absolute LR rates were numerically higher in patients without RT: 18.9% (RT) vs. 46.4% (no RT) for &lt;1mm, 6.7% (RT) vs. 25.0% (no RT) for 1-1.9mm and 6.0% (RT) vs. 5.5% (no RT) for ≥2mm. Conclusion: For patients undergoing BCS for DCIS with or without microinvasion, our findings support that re-excision can be selectively omitted for limited volume 1-1.9mm margins, as the 10-year LR rates are comparable to margins ≥2mm when followed by adjuvant RT. However, we advise caution against omission of re-excision for margins &lt;1mm given significantly higher rates of LR regardless of RT use. Citation Format: Cecily Stockley, Shiva Bahmanyar, Yuan Xu, Jeffrey Cao, May Lynn Quan, Alison Laws. 10-Year Local Recurrence Rates Following Selective Omission of Re-excision for Patients with Ductal Carcinoma in Situ and Margins [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2024; 2024 Dec 10-13; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2025;31(12 Suppl):Abstract nr P3-07-07.

Abstract P3-05-09: Invasive Lobular Carcinoma Has Aggressive Molecular Subtypes in African American Women

2025-06-13

Genevra Magliocco , Roy Khalifé , Anthony Magliocco | Clinical Cancer Research

Abstract Introduction: Breast cancer is a heterogeneous disease with many biological subtypes. Invasive lobular carcinoma (ILC) is a rarer subtype of increasing clinical importance, with distinct clinical pathological and molecular … Abstract Introduction: Breast cancer is a heterogeneous disease with many biological subtypes. Invasive lobular carcinoma (ILC) is a rarer subtype of increasing clinical importance, with distinct clinical pathological and molecular features that are not fully understood. The incidence of ILC is increasing compared to ductal carcinoma in the US. While the incidence of breast cancer is lower in African American/Black (AA/B) women compared to White women (W), mortality rates are disproportionately higher. The reasons for this disparity are unclear. The aim of this study is to better characterize the molecular features of lobular breast cancer and determine if differences exist between AA/B women compared to W women. Methods: The Cancer Genome Atlas firehose data set was analyzed in cBioPortal, comparing AA/B (n=16) and W (n=166) women with lobular breast cancer. Statistical tests including linear cox regression, Fisher’s exact test, and chi square analysis were performed using R (version 4.4.1, 2024). Variables included race, stage, age, and hormone receptor status. Analysis compared differences in overall and disease-free survival and interpreted molecular differences between the two groups. ClinVar was used to determine frequency of germline mutations in the general population. Results: There were no differences for distribution of age or stage between racial subgroups. Proportions for stage were 18.7% AA and 15.7% W for stage 1, 62.5% AA and 50.3% W for stage 2, and 18.8% AA and 33.9% W for stage 3. The median age was 59.3 for AA/B and 62.0 for W. Overall survival at 36 months was worse (76.7%) in AA/B compared to (94.6%) in W women with ILC (p=0.056). In this cohort, age and stage were not associated with differences in overall survival. Estrogen receptor (ER) negative status was more prevalent in AA/B subgroup with ILC (22%) compared to W women with ILC (2%). Overall survival at 36 months for patients with ER negative ILC was shortened compared to ER positive ILC (50% vs 98% respectively, p=0.0001). However, when separated by racial subgroup, ER status was not associated with differences in overall survival for AA/B vs. W. Patients with ER negative ILC were 14.29 times more likely to have a TP53 alteration compared to ER positive ILC (p= 0.002). TP53 mutation was more prevalent in AA/B (37.6%, n=6) compared to W (3.6%, n=6) in lobular cancer. Within the AA subgroup, disease free survival at 36 months for patients with TP53 alterations was 25% (n=5) compared to 100% for patients with unaltered TP53 (n=11) (p=0.0004). Within the W subgroup, patients with TP53 alterations were less common and associated with longer disease-free survival at 3 months (100%, n=6 for altered) compared to unaltered TP53 (89.5%, n=160) (p=0.50). Among the 6 AA/B patients with TP53 alterations, four had allele frequencies of 0.4-0.7, possibly suggestive of germline mutation. A search of ClinVar revealed two out of the four TP53 mutations were previously seen in Li Fraumeni syndrome (R248W, L255 del). Conclusion: Overall survival for ILC was worse in AA/B women compared to their W counterparts, consistent with existing literature. Differences in hormone status and inherited and somatic gene mutations were identified between racial subgroups. Among ILC there is an aggressive subtype characterized by ER negativity and TP53 mutations. This subtype may be more common in AA/B. These results suggest that some TP53 mutations in AA/B may be inherited; this could have implications for future targeted TP53 therapy in AA/B. However, analysis is limited by small sample size for AA/B women with ILC, and absence of detailed sociodemographic, treatment and outcome data. Future studies should include a larger size of AA/B, and control for sociodemographic and treatment variables. Citation Format: Genevra Magliocco, Roy Khalife, Anthony Magliocco. Invasive Lobular Carcinoma Has Aggressive Molecular Subtypes in African American Women [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2024; 2024 Dec 10-13; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2025;31(12 Suppl):Abstract nr P3-05-09.

Abstract P5-11-28: Management of triple-negative breast cancer in renal transplant patients: A case report and multidisciplinary approach

2025-06-13

Alexandra Montenegro , Diana Simão , Leonor Fernandes +1 more | Clinical Cancer Research

Abstract Introduction: In renal transplant (ReT) patients, the incidence of breast cancer (BC) is similar to the general population, albeit with a less favorable prognosis. The literature lacks guidelines for … Abstract Introduction: In renal transplant (ReT) patients, the incidence of breast cancer (BC) is similar to the general population, albeit with a less favorable prognosis. The literature lacks guidelines for the diagnostic and therapeutic approach to BC in ReT patients, thus recommendations are based on those for the general population. It is crucial to manage the oncological disease while preserving the function of the transplanted organ by preventing treatment toxicity and drug interactions between immunosuppressants and oncological treatments. Case Description: This report describes a 45-year-old woman who detected a painful lump in her left breast (LB), prompting further investigation. The patient underwent ReT in 2017 due to end-stage chronic kidney disease and is on immunosuppressive therapy (tacrolimus 3.5 mg daily and mycophenolate mofetil 250 mg twice daily). Her family history of cancer includes a brother diagnosed with gastric cancer at age 55.Further investigation of the LB mass revealed a suspicious nodular formation at the transition of the upper quadrants of the LB, measuring 18x14 mm and no suspicious axillary lymphadenopathy (LB BI-RADS 5). Breast MRI revealed a 50mm unilateral atypia. An ultrasound-guided core needle biopsy was performed, which showed a left breast carcinoma of no special type, grade II, estrogen receptor (ER) negative, progesterone receptor (PR) negative (both 0%), HER2 negative (0), and Ki67 60%. Contrast-free CT scan, abdominal ultrasound, and bone scintigraphy showed no suspicious secondary lesions. The patient was referred to Medical Oncology and Genetics consultations, given her young age and diagnosis of triple-negative breast cancer (TNBC) cT2N0M0.Neoadjuvant chemotherapy (NACT) based on taxanes and anthracyclines was proposed, followed by local therapy. During a nephro-oncology meeting, it was decided to conduct weekly monitoring of renal function (pre-NACT creatinine 1.82 mg/dL). The patient completed the planned NACT without dose reductions, delays or unexpected toxicities. Dose adjustments of immunosuppressants due to subtherapeutic levels were done. Post-NACT, renal function remained stable (post-NACT creatinine 1.72 mg/dL).The patient underwent a total mastectomy with sentinel lymph node biopsy due to large tumor-to-breast-size ratio. Complete pathological response (pCR) was achieved. At 12 months post-surgery, the patient remains free of disease recurrence. Discussion and Final Comments: We share a case of a ReT patient presenting a stage IIB TNBC diagnosed five years after the ReT. The patient underwent taxane-anthracycline NACT. There was renal graft function preservation and a pCR was achieved. This was facilitated by regular renal function monitoring and a multidisciplinary approach. However, nowadays, a combination of immunotherapy (IO) and chemotherapy is the standard of care. Lessons LearnedThere is a lack of literature addressing how to manage breast cancer in ReT. Breast Cancer Treatment in ReT patients can be extrapolated from the general population. A multidisciplinary approach is crucial and regular renal function monitoring is needed.Immunotherapy's role in solid organ transplant receipts is being debated. Citation Format: Alexandra Montenegro, Diana Cardoso Simão, Leonor Fernandes, Sónia Duarte Oliveira. Management of triple-negative breast cancer in renal transplant patients: A case report and multidisciplinary approach [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2024; 2024 Dec 10-13; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2025;31(12 Suppl):Abstract nr P5-11-28.

Abstract P5-02-27: Investigating the Prognostic Significance of Circulating Tumor Cells in Ductal Carcinoma In Situ Patients

2025-06-13

Neha Nagpal , Brittany Rupp , Hong Yan +3 more | Clinical Cancer Research

Abstract Raised awareness of the importance of early diagnostics in breast cancer is leading to an increased incidence of ductal carcinoma in situ (DCIS) being detected through mammographic screening. DCIS … Abstract Raised awareness of the importance of early diagnostics in breast cancer is leading to an increased incidence of ductal carcinoma in situ (DCIS) being detected through mammographic screening. DCIS is widely defined as a ‘Stage 0’ carcinoma with neoplastic cells still confined to the basement membrane. However, while most DCIS patients will receive widespread overtreatment for their carcinoma, the 20-year breast cancer mortality rate following a DCIS diagnosis, with or without treatment, remains at 3.3%. To better understand breast cancer carcinogenesis, recent studies have drawn attention to the clonal diversity within the DCIS tumor microenvironment and the presence of disseminated tumor cells in DCIS patients. However, there still exist gaps in understanding of characteristics at the time of diagnosis that make certain DCIS patients more likely to progress or recur. Ultimately, the goal of the project is to better inform DCIS patient risk stratification via the high throughput isolation and analysis of circulating biomarkers. In this study, we establish a workflow that targets the gaps in traditional tissue-based diagnostics by pivoting towards liquid biopsies. Our study not only builds on emerging literature on the early dissemination of breast cancer cells during carcinogenesis, but also investigates the value of circulating tumor cells (CTCs) as a biomarker in DCIS. To achieve a more holistic understanding of a patient’s carcinoma, we supplement our study with the Mouse INtraDuctal (MIND) models - an animal model that recapitulates the tumor microenvironment of DCIS in the mammary ducts of mice. We employed a high throughput, label-free microfluidic platform to enrich CTCs from DCIS patient samples. CTCs isolated from the unbiased platform were processed for single cell RNA sequencing along with white blood cells, red blood cells, and platelets that enabled further investigation of the circulating microenvironment and potential inter-cellular interactions. Further, to correlate findings in patient samples to an animal model wherein the timeline of progression to invasive disease can be shortened to 9 to 12 months (vs. 10+ years in patients), we analyzed blood samples from three different MIND models in a time course study over 12 months. Applying our workflow to 26 patient samples and 10 healthy controls, we identified CTCs in 96% of the patient samples. The average concentration of CTCs per mL of blood across all DCIS patients was significantly greater than that in the healthy controls (p &lt; 0.0001, Mann-Whitney U Test). Through single cell RNA sequencing, inferred CNVs were found in two cell clusters that also encapsulated potential CTCs based on presence of canonical epithelial cell markers but absence of white blood cell genes. An epithelial to mesenchymal cell phenotype score was calculated (scale 0 to 100, respectively) for each potential CTC, and it was found that the median score tended around 50 to 60, supporting expanding literature on the hybrid epithelial-to-mesenchymal state of CTCs. In addition, during the MIND model time course study, CTCs were found in circulation as early as 3 months after formation of the models and while the models were still pre-invasive. Overall, our study enables the assessment of CTCs as a prognostic biomarker for DCIS patients. By studying CTCs in patient samples and their derived MIND models in parallel, we aim to continue to build an understanding of the drivers behind early dissemination. Further experimentation is also being planned to study the original tumor at a single cell level in comparison to the blood sequencing that has already been performed. The overarching goal is to compose a more holistic understanding of the origin of these malignant cells in circulation. Ultimately, we hope to investigate the value of CTCs as a clinical biomarker to inform personalized risk stratification for DCIS patients. Citation Format: Neha Nagpal, Brittany Rupp, Yan Hong, Fariba Behbod, Max Wicha, Sunitha Nagrath. Investigating the Prognostic Significance of Circulating Tumor Cells in Ductal Carcinoma In Situ Patients [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2024; 2024 Dec 10-13; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2025;31(12 Suppl):Abstract nr P5-02-27.

Abstract P1-03-07: Identifying risk factors for Benign Breast Disease in Donors to the Komen Tissue Bank

2025-06-13

Rina Yadav , Vidya Patil , Jessica Moss +2 more | Clinical Cancer Research

Abstract Background: An estimated 1.6 million breast biopsies are performed annually in the United States. Most of these tissue samples are noncancerous and classified as benign breast disease (BBD). Women … Abstract Background: An estimated 1.6 million breast biopsies are performed annually in the United States. Most of these tissue samples are noncancerous and classified as benign breast disease (BBD). Women diagnosed with BBD are 2 times more likely to be diagnosed with breast cancer (BC) than women without BBD. Studies have shown that the increased risk of BC remains elevated for at least 20 years after a BBD diagnosis. Currently, there is no standard surveillance algorithm or society-guided treatment guidelines for these patients. Furthermore, scant literature guides BBD etiology and strategies for risk-stratification for future BC development. Variables such as hormone use, physical activity, diet, breast density, and genetics are associated with BBD and risk calculators (Gail and Tyrer-Cuzick scores) use some of these variables to help predict a patient’s risk of BC. However, neither of these models include smoking history in their assessment. Evidence supports that smoking is associated or causal with a wide range of cancers, but there is inconsistent data to prove its connection to BBD and/or BC. To further understand smoking and its relation to BBD and/or BC, breast tissue repositories, such as the Komen Tissue Bank (KTB) (established in 2007 at the Indiana University and is the only resource of normal, healthy breast tissue that is representative of the US population) can be utilized to evaluate modifiable behaviors, such as smoking. The aim of our study was to evaluate demographic, personal health, and modifying behaviors in females diagnosed with BBD versus those who have never had the need for a clinically indicated biopsy. Methods: Data from 5,118 individuals who donated to the KTB (2007–2023) were compiled into an analytic dataset. Men (n=37) and those with a baseline history of BC (n=206) were excluded. The final study population consisted of 4,875 women, those with a self-reported history of BBD (n = 807) versus those without BBD (n = 4,061). Characteristics including demographics, personal health, reproductive histories, and modifiable behaviors, were analyzed and compared using chi-square tests, and p-values of &lt;0.05 were considered to be statistically significantly different between the groups. The BC risk assessment scores (Tyrer-Cuzick and Gail Scores) were calculated for 3,447 participants (aged 35 to 85) between those with and without BBD, recognizing the women with BBD would likely be at higher risk. Results: Donors with BBD had increased frequencies of family histories (FH) of BC, being menopausal/older age, having prior hormone (HRT) use, and having mammograms (MMG) performed (p&lt;0.0001). Modifiable risk factors such as smoking were more common in individuals with BBD (p&lt;0.0001). However, alcohol and body mass index (BMI) did not differ between groups. Tyrer-Cuzick Scores in BBD patients had a 10% higher frequency of being intermediate risk for BC compared to those without BBD. Gail Scores in BBD patients had a 50% higher frequency of being intermediate risk for BC (p&lt;0.0001). Conclusions: In the KTB donors, there is an increased frequency of smoking in patients with BBD. Smoking is not a variable used in standard breast cancer risk calculators and data are inconsistent regarding smoking and BC. However, smoking is known to decrease circulating estrogen and result in women becoming menopausal two years earlier than their non-smoking counterparts. Dysregulation of estrogen levels and menopausal status are two critical variables known to increase one’s risk of BC. Clinicians should be aware of this potential risk factor and subsequently better educate patients who smoke about their increased risk of BBD and possible BC. Further research needs to be done to elucidate etiology, pathophysiology and management of BBD. Citation Format: Rina Yadav, Vidya Patil, Jessica Moss, Aradhana Kaushal, Michele L. Cote. Identifying risk factors for Benign Breast Disease in Donors to the Komen Tissue Bank [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2024; 2024 Dec 10-13; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2025;31(12 Suppl):Abstract nr P1-03-07.

Abstract P5-12-20: Clinicopathological Correlates of Immunohistochemistry Subtypes in Ductal Carcinoma In Situ: A Retrospective Analysis

2025-06-13

Jessica Chin , Donghee Kim , Young Joo Lee +3 more | Clinical Cancer Research

Abstract Introduction: Ductal carcinoma in situ (DCIS), an early neoplastic lesion confined within the mammary ductal system, exhibits considerable molecular heterogeneity, reflected in distinct immunohistochemistry (IHC) subtypes such as hormone … Abstract Introduction: Ductal carcinoma in situ (DCIS), an early neoplastic lesion confined within the mammary ductal system, exhibits considerable molecular heterogeneity, reflected in distinct immunohistochemistry (IHC) subtypes such as hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) status. It's well-established that while DCIS represents a non-obligate precursor to invasive breast cancer (BC), a subset of cases harbors the potential for progression to invasive disease. Understanding the intricate molecular landscape of DCIS, particularly the interplay between IHC subtypes and the propensity for invasive progression, holds paramount importance in clinical decision-making. This study aims to investigate how IHC subtypes such as ER, PR, and HER2 in DCIS correlate with the tumor's clinicopathological characteristics. Methods: We analyzed data from the Korean Breast Cancer Society registration database, focusing on patients aged 20 and older who underwent surgery for DCIS between 2000 and 2019. Patients with confirmed lymph node metastasis or distant metastasis were excluded from the analysis. Results: A total of 11,812 patients were analyzed. Among them, 7,427 (62.9%) had HR+/HER2- breast cancer (BC), 611 (5.2%) had triple-negative breast cancer (TNBC), 1,904 (16.1%) had HR-/HER2+ BC, and 1,870 (15.8%) had HR+/HER2+ BC. At the time of diagnosis, the median age was higher in HR-BC compared to HR+ BC (HR+/HER2-: 48years, HR+/HER2+: 49years, TNBC: 53years, HR-/HER2+: 53 years). Family history was more prevalent in HR+ BC (10.5%) compared to HR-BC (8%). The proportion of asymptomatic cases was higher in HR+ BC (HR+/HER2-: 39.9%, HR+/HER2+: 45.1%) compared to HR-BC (TNBC: 34.2%, HR-/HER2+: 35.5%). Among HR-BC, the percentage of cases with a palpable lump was higher (TNBC: 30.3%, HR-/HER2+: 26.3%). Bilateral BC was more common in HR+ BC (0.5%). Tumor size (median) was larger in HER2+ BC (HR+/HER2-: 1.1 cm, TNBC: 1.2 cm, HR+/HER2+: 1.5 cm, HR-/HER2+: 1.9 cm). Mastectomy was more frequent in HER2+ BC (HR+HER2+ 40.4%, HR-/HER2+: 51.6%). Regarding nuclear grade, HR+/HER2- BC had the lowest proportion of high-grade tumors (12.5%), while HR-/HER2+ BC had the highest (73.6%). Conclusion: This study reveals the diverse clinicopathological features of DCIS based on IHC subtypes, emphasizing the importance of molecular characterization in guiding clinical management decisions. Understanding these distinct profiles can enhance prognostication and facilitate tailored treatment approaches for patients with DCIS. Citation Format: Je Hyun Chin, Doo Reh Kim, Young Joo Lee, Chang Ik Yoon, Woo Chan Park, Soo Youn Bae. Clinicopathological Correlates of Immunohistochemistry Subtypes in Ductal Carcinoma In Situ: A Retrospective Analysis [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2024; 2024 Dec 10-13; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2025;31(12 Suppl):Abstract nr P5-12-20.